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Summary

Aim(s)
Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity. The aim was to develop a time-to-event model describing leflunomide cessation due to toxicity within a clinical cohort and to investigate potential predictors of cessation such as total and free teriflunomide exposure and pharmacogenetic influences. 
Methods
This study included individuals enrolled in the Early
Results
Data from 105 patients was analysed, with 34 ceasing due to toxicity. The baseline dropout hazard and baseline random censoring hazard were best described by step functions changing over discrete time intervals. No statistically significant associations with teriflunomide exposure metrics were identified. Of the screened covariates, carriers of the C allele of CYP1A2 rs762551 had a 2.29 fold increase in cessation hazard compared to non-carriers (95% CI 2.24 -2.34, p=0.016).
Conclusions
A time-to-event model described the time between leflunomide initiation and cessation due to side effects. The C allele of CYP1A2 rs762551 was linked to increased leflunomide toxicity, while no association with teriflunomide exposure was identified. Future research should continue to investigate exposure-toxicity relationships, as well as potentially toxic metabolites.
What is already known about this subject
 Leflunomide is an effective treatment option in RA yet approximately 20 to 40% of patients fail due to toxicity.  Teriflunomide's pharmacokinetics are highly variable, yet total concentrations have not been linked to toxicity, despite an association with response.
 Polymorphisms within CYP1A2, CYP2C19 and DHODH have previously been linked to toxicity.
Introduction
Leflunomide is a disease modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease associated with severe morbidity, reduced functional ability and increased mortality [1] . Meta-analyses have shown that leflunomide has comparable efficacy to methotrexate, the gold standard for RA treatment [2, 3] , and leflunomide is commonly used as a second line therapy option either as monotherapy or in combination with other conventional DMARDs in patients with resistant disease [4] [5] [6] . However, a major limitation for achieving remission with leflunomide is that up to 40% of patients discontinue therapy due to toxicity [2, 7, 8] . Gastrointestinal side effects (e.g. diarrhoea, nausea and vomiting; GI) are experienced by 20-30% of patients and are most likely to occur early in treatment and may settle if patients persist with therapy [8, 9] . In those who do not adequately respond to conventional DMARDs, biological DMARDs are considered [4] [5] [6] . In addition to being associated with an increased incidence of some cancers and serious infections [10] , these agents are costly, so maximising remission rates with less expensive therapies such as leflunomide is likely to be a worthwhile strategy to maintaining patient outcomes whilst reducing the financial burden association with biological agents.
Cytochrome P-450 enzymes (CYP) -1A2, -2C19 and 3A4 are responsible for the metabolism of leflunomide to teriflunomide (the active metabolite), and previous studies have shown that genetic polymorphisms in CYP1A2 and CYP2C19 may be linked to increased toxicity [11, 12] . Furthermore, polymorphisms in CYP2C19 have been associated with altered plasma concentration, but to date no association of concentration with CYP1A2 genotype or smoking has been seen [13] . A single nucleotide polymorphism (SNP) within the first exon of dihydroorotate dehydrogenase (DHODH, rs3213422, 19C>A), the primary target of teriflunomide, has also been linked to increased toxicity [14] . Previous cross-sectional studies have identified a relationship between total teriflunomide concentrations and leflunomide response in patients with RA, but no relationship with adverse drug events has been identified [13, 15, 16] . Plasma teriflunomide is highly bound to plasma proteins (>99%) [17] , and for many drugs with a high degree of protein binding, total concentrations may be a poor surrogate of the free concentrations which are responsible for exerting clinical effects [18] .
Studies have indicated variability between total and free teriflunomide concentrations [19, 20] , but as yet free concentrations have not been investigated for a link to toxicity or response in RA patients.
The aim of this study was to develop a time-to-event model [21] describing the cessation of leflunomide due to toxicity, and to investigate potential predictors of this outcome including total and free teriflunomide exposure and pharmacogenetic markers.
Methods
Software
Modelling was performed using a Dell® Power Edge R910 server with 4x10 core Xeon 2. Data manipulation, steady state concentration prediction, Kaplan-Meier analysis and survival model graphical output were conducted with the R Software Version 3.1.1 (R Core Team 2014) using the ggplot2, doBy, stringr, Hmisc, plyr, reshape2, gridExtra, scales, deSolve and survival packages [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
Study population
Participants were aged ≥18 years, diagnosed with DMARD-naïve RA according to revised ACR Criteria [32] and enrolled in the RA inception cohort at the Royal Adelaide Hospital (RAH) between 2000 and 2013. Exclusion from the study included insufficient clinical records during the follow up period. All participants were treated according to a previously published treat-to-target protocol [6] . At diagnosis 'triple therapy' (methotrexate, sulfasalazine and hydroxychloroquine) was initiated. Patients were generally assessed every six weeks during active disease, or every three months once disease was inactive. If RA was active according to pre-defined criteria [6] , sulfasalazine and then methotrexate were uptitrated to maximum tolerated doses. If this failed to control disease, leflunomide was added.
During the first three years of the cohort study, leflunomide was initiated with a loading dose (three daily doses of 100 mg followed by 20 mg daily). Subsequently, this practice changed to an initial daily dose of 10 mg, and in the case of persistent disease, the daily dose was increased to 20 mg. Patients gave informed written consent for inclusion in the inception cohort and provision of a DNA sample. Ethics approval was obtained from the Human Research Ethics Committee of the RAH and the University of South Australia.
Event time data
Study participants were followed for up to 60 weeks after leflunomide initiation. Participants either i) continued to take leflunomide throughout the study period and were censored at the clinic visit date 'closest' to 52 weeks, or if the closest' visit date was greater than 52 weeks, were censored from the study at 52 weeks ii) had another DMARD added (due to persistent disease activity) during the 60 week study period and were not considered to have ceased leflunomide due to side effects, but were censored at the date this new DMARD was added, or iii) ceased leflunomide due to side effects before 52 weeks. Treating clinicians were responsible for determining and recording the date of leflunomide cessation due to toxicity, with causality confirmed via a Naranjo categorisation of possible or greater [33] . predicted CYP2C19 'phenotype' and ABCG2 rs2231142 (C421A) genotype had all been determined prior to this study as described previously [12, 35, 36] . Predicted CYP2C19 'phenotype' was determined from rs4244285 and rs12248560 genotypes, and individuals were characterised as either unknown, ultra-rapid, extensive or poor and intermediate metabolisers, with unknown metabolisers imputed with the mode [12] . Haplotype, genotype or 'phenotype' grouping was conducted in the event of low allele frequencies (i.e. carriers of a homozygous recessive genotype with a frequency <10% were grouped with the heterozygous genotype).
Exposure metrics
Between 2010 and 2013, 69 participants involved in this study additionally gave informed written consent for collection of blood samples used to determine total and free teriflunomide concentrations, as previously described by Rakhila et al. [20] . Participants on a stable dose of leflunomide provided 2x10 mL blood samples collected at successive clinical visits (generally 6-12 weeks apart). Participants who initiated leflunomide between 2010 and 2013, had a blood sample collected before the first dose, followed by another at each of their next 5 clinic visits. All blood samples were collected as pre-dose trough samples.
For this data set, a semi-physiological pharmacokinetic model describing individual total and free teriflunomide concentrations, teriflunomide clearance (CLINT), volume of distribution (VBODY) and fraction unbound (FU) was developed [37] . From this model, empirical Bayes estimates of the physiological parameters controlling total and free teriflunomide concentrations were determined for each individual at their cessation or censor date. For individuals from whom no blood samples had been collected, physiological parameter estimates were imputed with the population median, as influenced by the individuals FFM and ALT concentrations [37] . Using the posteriori Bayes parameter estimates and the deSolve package of R, total and free teriflunomide steady state trough concentrations were predicted for each individual after 365 consecutive daily doses at the individual's average daily dose given across the study period. The average daily leflunomide dose across the study period and model predicted FU, CLINT and VBODY were also assessed as possible predictors of toxicity.
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Structural model development
The time to leflunomide cessation due to toxicity was described by a time-to-event model developed in a stepwise manner where (i) a base model without any explanatory factors, apart from time, was built and (ii) the effect of potential covariates on the rate of leflunomide toxicity were investigated.
The likelihood of not having ceased leflunomide due to toxicity at time t, was described by the parametric survival function, S(t). Where h(t) is the instantaneous hazard rate at time t, and S(t) is a function of the cumulative hazard function, H(t), between time zero and time t. As time-to-event models only use one observation for each individual, random effects on the baseline hazard could not be estimated, i.e. the same baseline hazard is assumed for all subjects. The probability density, f(t), of ceasing leflunomide at time t, was described by: Equation 3 Base models were developed by exploring different functions for base hazards, h 0 (t), starting with a constant hazard, then Weibull, Gompertz, log-logistic distributions and finally, step Equation 5 gives an example of a step function where the baseline hazard h 0 (t) changed depending on the time. Equation 5 A step function of this type was explored by starting with a single constant, and increasing the number of steps until no decrease in the AIC was observed. The time cut-offs for the steps were chosen based on the shape of a Kaplan-Meier plot of the raw data.
In order to facilitate simulation (see below), the random censoring of individuals before day 365 (e.g. cessation of leflunomide for reasons other than toxicity, having another DMARD added due to insufficient response or less than 365 days of follow-up) was also simultaneously described by a time-to-event model with its own h 0ran (t), S ran (t), H ran (t) and f ran (t).
Covariate model development
Covariates were screened according to biological plausibility and prior knowledge of the factors considered to influence leflunomide toxicity. Covariates were included within functions (λ cov ) developed to modify the base hazard, h 0 (t), to give the hazard function, h(t): Equation 6 This article is protected by copyright. All rights reserved. Equation 8 Equation 9 The potential inclusion of covariates on the base model were selected based upon a significant decrease in OBJ (p<0.05). The final model was developed via forward inclusion, where each covariate was sequentially added, starting with the covariate that caused the largest drop in the OBJ, and the following covariate(s) were only retained if the selection criteria were met.
Model evaluation and simulation
For the final structural and covariate models, nonparametric bootstrap analysis was used to assess the uncertainty of the parameter estimates. The original dataset was resampled 1000 times and analysed to estimate the 95% confidence intervals (95% CI) of the model parameters.
Time-to-event model visual predictive checks were used to assess the ability of the final structural and covariate models to describe the data [21, 38] . Using the R survival package, the survival probability of 1000 simulated replicate populations was computed at half daily intervals. The median and 95% CI of these survival probabilities were visually compared This article is protected by copyright. All rights reserved.
against the Kaplan-Meier plot with 95% CI of the original dataset. To enable simulation, daily intervals from 1 to 365 were added to the original data for each individual. Covariate information was added to these additional records by a last observation carried forward/previous observation carried backward approach. The probability that an individual would be randomly censored (Equation 10) or cease leflunomide due to toxic effects (Equation 11) during an interval (i.e. a day) were respectively represented by conditional probabilities of failure, :
Equation 11 In NONMEM, the conditional probabilities of random censoring and cessation were compared against two randomly generated uniform numbers between 0 and 1, representing the individual's probability of remaining in the study or ceasing leflunomide during that time period. If at time t 2 , was greater than the corresponding random number, the individual was said to have ceased leflunomide if they had not previously been lost to follow up due to a random censoring occurrence (i.e. had at a previous time been greater than its corresponding random number).
Results
Patients
A total of 115 patients commenced leflunomide and 10 were excluded due to incomplete records, leaving 105 participants available for analysis. Their baseline characteristics and teriflunomide exposure metrics are described in Table 1 .
Of the 105 patients, 34 (32.4%) ceased leflunomide due to toxicity before day 365 of treatment. The side effects that contributed to the cessation of leflunomide are indicated in Two baseline DAS28 were missing from the data set and these were imputed with the median. RF, anti-CCP and SE status were imputed with the mode for one, two and four participants respectively, while CYP2C19 phenotype [12] was unpredictable for eight individuals, who were similarly imputed with the mode. Blood samples were only available from 69 of the 105 participants, and thus participants with no samples had physiological parameter estimates that were imputed with the median as adjusted for the individuals ALT and FFM. These parameter estimates were used to predict the individuals total and free steady state trough teriflunomide concentration based upon their average leflunomide dose.
Structural model
The hazard functions h 0 (t) and h 0ran (t) that best described the data with regards to AIC and visualisation against the original dataset Kaplan-Meier plot were step functions. For h 0 (t), results were best described by four time intervals, each with its own constant hazard rate, whereas h 0ran (t) was best described by five time intervals. The resulting cessation hazard, h 0 (t), was high for the first 50 days, followed by a lesser decrease until day 112, after which it was higher until day 204, before another lesser decrease until the end of the study period.
Conversely random censoring hazard, h 0ran (t), increased significantly when comparing the first time interval against the final (Table 3) .
Covariate model
Of the screened covariates, only CYP1A2 C163A allele status met the inclusion criteria and no teriflunomide exposure covariates were identified ( Table 4 ).
The 51 carriers of the C allele at CYP1A2 C163A (i.e. CC or CA genotype) had a 2.29 fold (95% CI = 2.24 -2.34) increase in cessation hazard compared to the 54 A homozygotes. The OBJ (1036.75) was 5.80 lower than with the structural model (p=0.016). Parameter estimates of the covariate model and the precision of these estimates are represented in Table 3 . 
Discussion
A time-to-event model successfully described the time from leflunomide initiation until cessation due to toxicity in 105 RA patients taking leflunomide, most of whom were concurrently receiving other DMARDs. The cessation hazard was best described by a step function of four constants, while of 23 potential covariates, only CYP1A2 C163A allele status significantly influenced the occurrence of toxicity.
The analysis showed cessation hazard was highest from days 0 to 50 and 112 to 204. No information was available that could explain this phenomenon, although it is possible that it was related to the scheduling of patients clinic visits. Intensive clinical follow-up occurred in patients with active disease compared to less frequent visits for those in remission, and there was an overall tendency to see individuals at three and six months intervals, which corresponds to the periods of high dropout. Future research will aim to establish the external validity of the step functions, as despite describing the present population very well, the likelihood of describing an alternate population from a different recruitment site may be limited.
Previously, the CC genotype at CYP1A2 C163A has been associated with a 9. [39] . In the present study carriers of one or more C alleles at CYP1A2
C163A had a 2.29 fold increase in instantaneous cessation hazard compared to non-carriers (95%CI= 2.24 -2.34, p=0.016). The C163A SNP is located in the promoter region of the CYP1A2 gene, and carriage of the A allele has been associated with enhanced metabolism of CYP1A2 substrates, particularly in cigarette smokers [11, 39] . However no association between smoking and leflunomide cessation was found. However, this is not surprising, as the rate of smoking (37.1%) in this study was small. Therefore as human liver microsome studies have suggested that CYP1A2, CYP2C19, and CYP3A4 are involved in the conversion of leflunomide to teriflunomide [40] , carriers of the C allele may have lower teriflunomide concentrations. To date however, this has not been observed [13] , which may be due to small sample sizes that have been unable to detect relatively small differences in teriflunomide concentrations that have high inter-patient variability, and/or CYP2C19 and CYP3A4 are able to maintain the high conversion of leflunomide to teriflunomide in individuals who carry a C allele at CYP1A2 C163A. Furthermore, reduced CYP1A2 activity may promote altered metabolism that result in significant increases in alternate toxic metabolites that are ordinarily at very low concentrations, or direct toxicity from leflunomide, both of which have been proposed previously [12, 19] .
In this study, we aimed to investigate potential predictors of leflunomide toxicity with a major focus on total and free teriflunomide concentrations. Predicted steady state trough concentrations at the individuals' average dose across the study period was preferred over the actual teriflunomide concentration at drop-out, due to teriflunomide's long half-life (mean ~ 15.7 days), where approximately 8 weeks is required to achieve steady state [17, 41] .
Instantaneous concentrations, particularly early in treatment and after dose changes, are highly time dependent and as such are imperfectly handled within time-to-event models, and are thus not a good metric to relate to toxicity between individuals on leflunomide for varying time lengths. Additionally, trough concentrations were used as they are subject to the influences of distribution effects, as well as clearance, which is the parameter solely responsible for the average steady state concentration. Therefore, predicted steady state trough concentrations were assessed, although to do this clinically, access to a population pharmacokinetic model, such as that used in this study [37] , would be required. Despite this, no association was found, although we acknowledge that in this study, blood samples were only available from 69 of 105 participants, and given the high variability of teriflunomide concentrations, the population median (adjusted for the individuals ALT and FFM) is likely to underestimate the variability in individual concentrations within the 36 imputed subjects.
Previously, Chan et al. [16] and Grabar et al. [13] investigated a possible relationship between total steady-state teriflunomide concentrations and adverse drug events in 23 and 67 RA patients, respectively, and found no association. These studies however were cross sectional, with leflunomide mostly being used as monotherapy with some participants having been on leflunomide for long periods and therefore selecting individuals who were tolerant of leflunomide. Furthermore, for many drugs free concentrations are more predictive of response and toxicity than total concentrations, particularly for those with a high degree of protein binding, such as teriflunomide, where the total concentration may be a poor surrogate of the free concentration [18, 20] . For the first time, predicted free steady-state teriflunomide concentrations have been investigated for a relationship with cessation of leflunomide due toxicity, although similar to previous studies, no association was found. Nor was an association found with the pharmacokinetic parameters (CLINT, VBODY or FU) predicted for each patient using our previously published model [37] , or with the individual's average daily leflunomide dose across the study period.
In this study, multiple covariates were screened, of which CYP1A2 C163A genotype was seen to result in a statistically significant effect on leflunomide cessation rate. In the occurrence of multiple covariates being included on forward inclusion, a backward deletion procedure (p<0.005) was planned for robustness of multiple hypothesis testing, although this was ultimately not possible given the single significant covariate that was identified. This study is not only the first study to assess the association between free teriflunomide concentration and leflunomide cessation, it is also the first to assess leflunomide cessation due to toxicity through the use of a time-to-event model within NONMEM. In contrast, previous studies have used binary logistic regression [11, 14] , which assesses hazard at distinct time points rather than across time, or cox proportional hazard models which are restricted to assuming that hazard rates change proportionally with covariates across time [12] . This study used a time-to-event model and found a step function with changing hazard across time to best describe leflunomide cessation, while conducting the analysis within NONMEM allowed simulation of the effect of CYP1A2 genotype, which has not been represented previously. Simulation highlights that although within our population the CYP1A2 genotype effects on leflunomide cessation was large with parameter estimates that are precise (%RSE of all parameters <2.15%), as the confidence intervals of the genotypes overlap, in some populations the effects of CYP1A2 C163A may not be statistically significant with a sample size of 105 participants.
This study did not confirm the findings of a number of other studies, including that of Grabar et al. [14] who previously reported an association between DHODH rs3213422 genotype and toxicity. As previously described there are several differences between the presented cohort and that studied by Grabar et al. [14] , who assessed toxicity through binary logistic regression. This study did not confirm the finding of an association between CYP2C19 phenotype and cessation of leflunomide due to toxicity found by Wiese et al. [12] , who assessed toxicity within the same cohort as used in this study (although the prior study finalised recruiting in 2011). In the present study, recruiting completed in 2013 and there were 105 eligible participants compared to the 78 assessed previously. This study also included longer follow-up in some participants, and identified some whom had ceased leflunomide but were restarted at a lower dose, hence explaining the moderately lower cessation rate. Furthermore, participants in this study with an undeterminable CYP2C19 phenotype (7.6%) were imputed with the mode, in contrast these participant were previously excluded. Wiese et al. [12] used a cox proportional hazard model including covariates previously associated with leflunomide cessation, assuming a cessation trend was present (p<0.25; current leflunomide dose, triple therapy and positive rheumatoid factor at diagnosis) [12] . Furthermore, Wiese et al. [12] analysed the association with CYP2C19 phenotype via a linear test for trend. The present study assessed cessation through a time-to-event model where covariates underwent a stricter inclusion criterion and categorical covariates were incorporated through a binary relationship.
Due to the observational nature of the study, the assessment of patient compliance was limited to reporting upon questioning at clinic visits, and although efforts were made to ensure all reported adverse events attributed to leflunomide were related and caused by leflunomide (as opposed to another DMARD or medication), certainty cannot be guaranteed.
Also, due to the relatively small patient numbers and inability to precisely ascertain the relative severity of each side effect and, therefore the one primarily responsible for cessation, subgroup analysis of covariate effects on particular side effects was not conducted within this study.
In the present study, cessation was high early after leflunomide initiation, and due to teriflunomide's long half-life, plasma concentrations would be relatively low in patient ceasing early compared to those who continue therapy long term. Previous research has
shown that individuals predominately cease leflunomide early due to GI side effects, especially with the use of the loading dose [42] ; as such it appears likely these side effects are related to local effects rather than being linked to teriflunomide plasma concentrations.
Therefore the subdivision of side effect appears important for future research as it may elucidate that side effects such as hepatotoxicity, pancytopenia and pneumonitis are related to high teriflunomide concentrations in the plasma, while the causes of GI side effects are related to local drug concentration not assessed in this study [8, [43] [44] [45] . Furthermore as CYP1A2 genotype has now independently been indicated as a determinant of leflunomide toxicity, future studies should focus upon investigating previously proposed toxic metabolites [12, 19] , that may be directly responsible for observable concentration dependent toxicity.
Furthermore investigating alternate significant polymorphisms within the CYP1A2 gene may elucidate different toxicity profiles within the leflunomide treated population, as the assessed polymorphisms within this study are not the only ones to be associated with altered enzymatic activity.
In conclusion, a time-to-event model describing time between leflunomide initiation and cessation due to side effects highlighted a significant association between CYP1A2 C163A genotype and toxicity. And despite the large amount of random censoring which occurred, the simultaneous description of censoring hazard enabled the effect to be visualised via simulation. No association between the assessed teriflunomide exposure metrics and toxicity driven cessation was found; however given the missing the blood samples from a section of the cohort, future research should to continue to investigate the relationship, as well as characterising the impact of potentially toxic metabolites. Abbreviations -disease activity score in 28 joints (DAS28), anti-citrullinated protein antibody (Anti-CCP), rheumatoid factor (RF), shared epitope (SE), fat free mass (FFM), methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), alanine transaminase (ALT), aspartate transaminase (AST), creatinine clearance (CrCl) and fraction unbound (FU). The covariates of baseline DAS28, SE status, weight, height, FFM, smoking status, ABCG2 genotype, CrCl, FU, CLINT, VBODY and predicted total teriflunomide steady state trough concentrations did not result in any improvement in the OBJ. Abbreviations -alanine transaminase (ALT), aspartate transaminase (AST), sulfasalazine (SSZ), anticitrullinated protein antibody (Anti-CCP, methotrexate (MTX), hydroxychloroquine (HCQ), rheumatoid factor (RF), disease activity score in 28 joints (DAS28), shared epitope (SE), fat free mass (FFM), creatinine clearance (CrCL) and fraction unbound (FU). *-represent covariates that were measured at cessation or censor date
